Literature DB >> 14731332

Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594).

M D Fisher, A D'Orazio.   

Abstract

Entities:  

Year:  2000        PMID： 14731332

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  16 in total

1.  Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis.

Authors:  Q Xu; Y Wang; H Liu; S Meng; S Zhou; J Xu; G Schmid-Bindert; C Zhou
Journal:  Clin Transl Oncol       Date:  2013-02-22       Impact factor: 3.405

2.  Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study.

Authors:  Jie Liu; Hong-Sheng Lin; Wei Hou; Bao-Jin Hua; Pei-Tong Zhang; Jie Li; Shen-Yu Wang; Ying Xie; Yue Zhang; Guang-Ru Xie; Mei-Ying Zhang; Wen-Guang Shi; Nian-Bo Guan; Tian-Yu Guan; Cong-Huang Li; Li-Yuan Lu; Ying Zhang; Dao-Rui Li; Hao Liu
Journal:  Chin J Integr Med       Date:  2016-10-28       Impact factor: 1.978

3.  Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.

Authors:  Charles Butts; Andrew Maksymiuk; Glenwood Goss; Denis Soulières; Ernie Marshall; Yvon Cormier; Peter M Ellis; Allan Price; Ravinder Sawhney; Frank Beier; Martin Falk; Nevin Murray
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-09       Impact factor: 4.553

4.  Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.

Authors:  Tian Yang; Mingwei Chen; Tianjun Chen; Asmitananda Thakur
Journal:  Oncol Lett       Date:  2015-07-24       Impact factor: 2.967

Review 5.  The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials.

Authors:  L L Zhang; F F Cao; Y Wang; F L Meng; Y Zhang; D S Zhong; Q H Zhou
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

6.  Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.

Authors:  Yulong Zheng; Weijia Fang; Jing Deng; Peng Zhao; Nong Xu; Jianying Zhou
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

7.  Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.

Authors:  Xiaoxia Chen; Ling Zhang; Shengxiang Ren; Xuefei Li; Fei Zhou; Wei Li; Guanghui Gao; Yayi He; Caicun Zhou
Journal:  Med Oncol       Date:  2014-02-18       Impact factor: 3.064

8.  Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).

Authors:  Luo Hu; Gong Liang; Wang Yuliang; Zhu Bingjing; Zhou Xiangdong; Xu Rufu
Journal:  Trials       Date:  2013-02-15       Impact factor: 2.279

9.  Pulmonary tuberculosis with false-positive 18F-fluorodeoxyglucose positron emission tomography mimicking recurrent lung cancer: A case report.

Authors:  Cheng Chen; Ye-Han Zhu; Hong-Ying Qian; Jian-An Huang
Journal:  Exp Ther Med       Date:  2014-11-07       Impact factor: 2.447

10.  Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study.

Authors:  V Surmont; J G J V Aerts; K Y Tan; F Schramel; R Vernhout; H C Hoogsteden; R J van Klaveren
Journal:  J Oncol       Date:  2009-11-12       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.